Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 2Breast Neoplasms 2Treatment for Metastatic or Locally Advanced Cervical Cancer 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 10Paclitaxel 8Bevacizumab 7Cyclophosphamide 6olaparib 5niraparib 5Fulvestrant 4talazoparib 3Radiotherapy 3Gemcitabine 3Capecitabine 3veliparib 2palbociclib 2eribulin 2dostarlimab 2aldesleukin 2Trastuzumab 2Specimen Handling 2Letrozole 2Drug Therapy 2Doxorubicin 2Cisplatin 2Celecoxib 2Biopsy 2Albumin-Bound Paclitaxel 2tucotuzumab celmoleukin 1trastuzumab duocarmazine 1trastuzumab biosimilar HLX02 1sotigalimab 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Ovarian Neoplasms × NVP-BKM120 × Clear all
NCT02117817 2022-07-28

Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer

Rutgers, The State University of New Jersey

Phase 1 Withdrawn
Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡